A large new study conducted in Spain and Italy found that beta blockers, drugs often used to slow the heart rate and lower blood pressure, did not provide clear benefits for heart attack patients ...

The REBOOT trial enrolled more than 8,400 patients recovering from a heart attack whose heart function was above 40% and assigned them to either take a beta blocker or no beta blocker within two weeks ...

Beta-blockers are still crucial for some, but new research calls into question the benefit for a large proportion of patients ...

Beta blockers have long been widely prescribed for patients with heart issues, but two new studies this week question the benefit of the therapies in certain patients with strong heart function. One ...

For over 40 years, beta blockers have been a cornerstone of treatment for heart attack survivors, but new research raises critical questions about their efficacy. The recent REBOOT trial has found ...

In a groundbreaking revelation for cardiology, recent findings from the REBOOT trial challenge the long-held belief that beta blockers are essential for heart attack survivors. This international ...